Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir

被引：25

作者：

Fulcher, Jennifer A. ^{[1
,2
]}

Du, Yushen ^{[3
]}

Zhang, Tian-Hao ^{[3
]}

Sun, Ren ^{[3
]}

Landovitz, Raphael J. ^{[1
,4
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, 10833 Le Conte Ave,CHS 37-121, Los Angeles, CA 90095 USA

[2] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[4] Ctr AIDS Res & Educ, Los Angeles, CA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2018年 / 67卷 / 05期

关键词：

antiretroviral therapy; drug resistance; integrase strand transfer inhibitors; ANTIRETROVIRAL-NAIVE ADULTS; ONCE-DAILY DOLUTEGRAVIR; HIV-1; INFECTION; DOUBLE-BLIND; RALTEGRAVIR;

D O I：

10.1093/cid/ciy228

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

引用

收藏

页码：791 / 794

页数：4

相关论文

共 13 条

[1] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].

Cahn, Pedro ;

Pozniak, Anton L. ;

Mingrone, Horacio ;

Shuldyakov, Andrey ;

Brites, Carlos ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary ;

Beltran Buendia, Carlos ;

Fourie, Jan ;

Ramgopal, Moti ;

Hagins, Debbie ;

Felizarta, Franco ;

Madruga, Jose ;

Reuter, Tania ;

Newman, Tamara ;

Small, Catherine B. ;

Lombaard, John ;

Grinsztejn, Beatriz ;

Dorey, David ;

Underwood, Mark ;

Griffith, Sandy ;

Min, Sherene .

LANCET, 2013, 382 (9893) :700-708

[2] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study [J].

Clotet, Bonaventura ;

Feinberg, Judith ;

van Lunzen, Jan ;

Khuong-Josses, Marie-Aude ;

Antinori, Andrea ;

Dumitru, Irina ;

Pokrovskiy, Vadim ;

Fehr, Jan ;

Ortiz, Roberto ;

Saag, Michael ;

Harris, Julia ;

Brennan, Clare ;

Fujiwara, Tamio ;

Min, Sherene .

LANCET, 2014, 383 (9936) :2222-2231

[3] Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades [J].

Doyle, Tomas ;

Dunn, David T. ;

Ceccherini-Silberstein, Francesca ;

De Mendoza, Carmen ;

Garcia, Frederico ;

Smit, Erasmus ;

Fearnhill, Esther ;

Marcelin, Anne-Genevieve ;

Martinez-Picado, Javier ;

Kaiser, Rolf ;

Geretti, Anna Maria .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (11) :3080-3086

[4] Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? [J].

Koullias, Yiannis ;

Sax, Paul E. ;

Fields, Naomi F. ;

Walensky, Rochelle P. ;

Hyle, Emily P. .

CLINICAL INFECTIOUS DISEASES, 2017, 65 (08) :1274-1281

[5] Emergent drug resistance with integrase strand transfer inhibitor-based regimens [J].

Lepik, Katherine J. ;

Harrigan, P. Richard ;

Yip, Benita ;

Wang, Lu ;

Robbins, Marjorie A. ;

Zhang, Wendy W. ;

Toy, Junine ;

Akagi, Linda ;

Lima, Viviane D. ;

Guillemi, Silvia ;

Montaner, Julio S. G. ;

Barrios, Rolando .

AIDS, 2017, 31 (10) :1425-1434

[6] Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial [J].

Raffi, Francois ;

Jaeger, Hans ;

Quiros-Roldan, Eugenia ;

Albrecht, Helmut ;

Belonosova, Elena ;

Gatell, Jose M. ;

Baril, Jean-Guy ;

Domingo, Pere ;

Brennan, Care ;

Almond, Steve ;

Min, Sherene .

LANCET INFECTIOUS DISEASES, 2013, 13 (11) :927-935

[7] Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update [J].

Shafer, Robert W. .

JOURNAL OF INFECTIOUS DISEASES, 2017, 216 :S843-S846

[8] Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment Outcomes [J].

Simen, Birgitte B. ;

Simons, Jan Fredrik ;

Hullsiek, Katherine Huppler ;

Novak, Richard M. ;

MacArthur, Rodger D. ;

Baxter, John D. ;

Huang, Chunli ;

Lubeski, Christine ;

Turenchalk, Gregory S. ;

Braverman, Michael S. ;

Desany, Brian ;

Rothberg, Jonathan M. ;

Egholm, Michael ;

Kozal, Michael J. .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (05) :693-701

[9] The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure [J].

Stella-Ascariz, Natalia ;

Ramon Arribas, Jose ;

Paredes, Roger ;

Li, Jonathan Z. .

JOURNAL OF INFECTIOUS DISEASES, 2017, 216 :S847-S850

[10]

Taiwo BO, 2017, 9 IAS C HIV SCI IAS